A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB) (PRESENCE)
A randomized placebo-controlled trial to evaluate the safety and efficacy of three doses of study drug LY3154207 treated for 12 weeks in participants with mild-to-moderate dementia associated with LBD (PDD or DLB).
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participant must have dementia
Participant must have Parkinson's Disease or dementia with Lewy bodies
Participants on anti-parkinsonian agents, must be on stable doses for at least 3 weeks prior to entering study
Participants on antidepressant medications, must be on stable doses for at least 3 weeks prior to entering study
Participants on blood pressure lowering medications, must be on stable doses for at least 3 weeks prior to entering study
Male participant must use appropriate contraception
Female participant must not be of childbearing potential
Participant must have a reliable caregiver who is in frequent contact with participant and will accompany participant to select visits
Participants Must Not:
Participant must not have a history of stroke in the last 6 months
Participant must not have a current or any previous diagnosis of bipolar disorder, schizophrenia, or other primary psychotic disorder
Participant must not have a history of substance abuse within the past 1 year, and/or substance dependence within the past 1 year, not including caffeine and nicotine
Lilly Trial Alerts
You will complete the questionnaire on another website.YesNo